Loading the section…

HSCS: financial statements from SEC — TradeAlmanac

HSCS

HeartSciences Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/01/2026	31/10/2025	31/07/2025	31/01/2025	31/10/2024	31/07/2024
Revenue	0	2,419	1,900	0	—	—
Cost of revenue	0	1,008	760	0	—	—
Gross profit	0	1,411	1,140	0	—	—
Research and development	638,575	727,026	997,206	1M	1M	1M
Selling, general and administrative	1M	1M	878,053	1M	786,068	850,736
Operating expenses	2M	2M	2M	2M	2M	2M
Operating income	−2M	−2M	−2M	−2M	−2M	−2M
Net income	−2M	−2M	−2M	−3M	−2M	−2M
Earnings per share	−0.63	−0.85	−1.58	−2.57	−2.27	−2.64
Earnings per share, diluted	—	−0.85	−1.58	−2.57	−2.27	−2.64
Weighted average shares	3M	3M	1M	986,057	917,445	777,746
Weighted average shares, diluted	—	3M	1M	986,057	917,445	777,746

Balance sheet

Metric	31/01/2026	31/10/2025	31/07/2025	30/04/2025	31/01/2025	31/10/2024	31/07/2024	30/04/2024
Cash and equivalents	3M	2M	3M	1M	3M	4M	4M	6M
Receivables	0	—

Cash flow

Metric	31/07/2025	31/07/2024
Operating cash flow	−2M	−2M
Depreciation and amortisation	7,111	11,864
Share-based compensation	174,558	54,554
Investing cash flow	−814	−833
Financing cash flow	4M	551,683

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator